A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia

Blume-Peytavi, Ulrike; Lönnfors, Sanna; Hillmann, Kathrin; Bartels, Natalie Garcia

doi:10.1016/j.jaad.2011.05.026

Cited by 113 publications

(78 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, a randomized comparison study evaluated the use of topical latanoprost 0.1% versus placebo in 16 men with mild (Hamilton II–III) patterned alopecia who applied the solutions daily to two minizones of the scalp. At 24 weeks, there was a significant increase in hair density of both terminal and vellus hairs on the latanoprost-treated site when compared to baseline and to the placebo-treated site 92. Fifty percent were defined as having a “good clinical response” (treatment better than placebo in at least two of the study criteria), 44% had “no clinical response” (no difference between placebo and treatment), and 6% had a “bad clinical response” (placebo better than treatment).…”

Section: Treatmentmentioning

confidence: 95%

Female pattern alopecia: current perspectives

Levy¹,

Emer²

2013

IJWH

View full text Add to dashboard Cite

Hair loss is a commonly encountered problem in clinical practice, with men presenting with a distinctive pattern involving hairline recession and vertex balding (Norwood-Hamilton classification) and women exhibiting diffuse hair thinning over the crown (increased part width) and sparing of the frontal hairline (Ludwig classification). Female pattern hair loss has a strikingly overwhelming psychological effect; thus, successful treatments are necessary. Difficulty lies in successful treatment interventions, as only two medications – minoxidil and finasteride – are approved for the treatment of androgenetic alopecia, and these medications offer mediocre results, lack of a permanent cure, and potential complications. Hair transplantation is the only current successful permanent option, and it requires surgical procedures. Several other medical options, such as antiandrogens (eg, spironolactone, oral contraceptives, cyproterone, flutamide, dutasteride), prostaglandin analogs (eg, bimatoprost, latanoprost), and ketoconazole are reported to be beneficial. Laser and light therapies have also become popular despite the lack of a profound benefit. Management of expectations is crucial, and the aim of therapy, given the current therapeutic options, is to slow or stop disease progression with contentment despite patient expectations of permanent hair regrowth. This article reviews current perspectives on therapeutic options for female pattern hair loss.

show abstract

Section: Treatmentmentioning

confidence: 95%

Female pattern alopecia: current perspectives

Levy¹,

Emer²

2013

IJWH

View full text Add to dashboard Cite

show abstract

“…There is one study in men showing that lanatoprost 0.1% increased scalp hair density compared to baseline and placebo (73) but the study included only 16 male patients and the medication was applied to a very small area of the scalp. Different classes of prostaglandins seem to have opposite actions in the hair follicle.…”

Section: Treatment Of Fphlmentioning

confidence: 99%

Female Pattern Hair Loss

Herskovitz

Tosti

2013

Int J Endocrinol Metab

View full text Add to dashboard Cite

Context:Female pattern hair loss (FPHL) also known as female androgenetic alopecia is a common condition afflicting millions of women that can be cosmetically disrupting. Prompt diagnosis and treatment are essential for obtaining optimal outcome.This review addresses the clinical presentation of female pattern hair loss, its differential diagnosis and treatment modalities.Evidence Acquisition:A) Diffuse thinning of the crown region with preservation of the frontal hairline (Ludwig’s type)B) The “Christmas tree pattern” where the thinning is wider in the frontal scalp giving the alopecic area a triangular shaped figure resembling a christmas tree.C) Thinning associated with bitemporal recession (Hamilton type).Generally, FPHL is not associated with elevated androgens.Less commonly females with FPHL may have other skin or general signs of hyperandrogenism such as hirsutism, acne, irregular menses, infertility, galactorrhea and insulin resistance. The most common endocrinological abnormality associated with FPHL is polycystic ovarian syndrome (PCOS).Results:The most important diseases to consider in the differential diagnosis of FPHL include Chronic Telogen Effluvium (CTE), Permanent Alopecia after Chemotherapy (PAC), Alopecia Areata Incognito (AAI) and Frontal Fibrosing Alopecia (FFA). This review describes criteria for distinguishing these conditions from FPHL.Conclusions:The only approved treatment for FPHL, which is 2% topical Minoxidil, should be applied at the dosage of 1ml twice day for a minimum period of 12 months. This review will discuss off-label alternative modalities of treatment including 5-alfa reductase inhibitors, antiandrogens, estrogens, prostaglandin analogs, lasers, light treatments and hair transplantation.

show abstract

“…Clinical trials evaluating bimatoprost in women with female pattern hair loss were recently completed while enrollment for a trial to assess bimatoprost in male pattern hair loss is ongoing (ClinicalTrials.gov identifier: NCT01904721) [201]. The results of the first trial are yet to be reported, however, a pilot study was performed with latanoprost, a prostaglandin F2a analog, whereby 50% of patients had increased hair growth [52]. These results would suggest that F2a analogs are a promising avenue to pursue for hair loss therapies.…”

Section: Drug Discovery Using Hair Follicle Organ Culturesmentioning

confidence: 99%

Regenerative Medicine and Hair Loss: How Hair Follicle Culture has Advanced our Understanding of Treatment Options for Androgenetic Alopecia

Christiano

2013

Regen. Med.

View full text Add to dashboard Cite

Many of the current drug therapies for androgenetic alopecia were discovered serendipitously, with hair growth observed as an off-target effect when drugs were used to treat a different disorder. Subsequently, several studies using cultured cells have enabled identification of hair growth modulators with similar properties to the currently available drugs, which may also provide clinical benefit. In situations where the current therapeutics do not work, follicular unit transplantation is an alternative surgical option. More recently, the concept of follicular cell implantation, or hair follicle neogenesis, has been attempted, exploiting the inherent properties of cultured hair follicle cells to induce de novo hair growth in balding scalp. In this review, we discuss both the advances in cell culture techniques that have led to a wider range of potential therapeutics to promote hair growth, in addition to detailing current knowledge on follicular cell implantation, and the challenges in making this approach a reality.

show abstract

A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia

Cited by 113 publications

References 24 publications

Female pattern alopecia: current perspectives

Female pattern alopecia: current perspectives

Female Pattern Hair Loss

Regenerative Medicine and Hair Loss: How Hair Follicle Culture has Advanced our Understanding of Treatment Options for Androgenetic Alopecia

Contact Info

Product

Resources

About